Education
About Us
Working with TipRanks
Follow Us
Kronos Bio (KRON)
NASDAQ:KRON
Total Valuation
Kronos Bio has a market cap or net worth of $47.42M. The enterprise value is -$30.20M.
Market Cap$47.42M
Enterprise Value-$30.20M
Share Statistics
Kronos Bio has 60.97M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60.97M
Owened by Insiders27.35%
Owened by Instutions17.71%
Financial Efficiency
Kronos Bio’s return on equity (ROE) is -0.98 and return on invested capital (ROIC) is -82.58%.
Return on Equity (ROE)-98.29%
Return on Assets (ROA)-69.22%
Return on Invested Capital (ROIC)-82.58%
Return on Capital Employed (ROCE)-85.15%
Revenue Per Employee$984,800
Profits Per Employee-$8,607,900
Employee Count10
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kronos Bio is -0.66. Kronos Bio’s PEG ratio is 0.02.
PE Ratio-0.66
PS Ratio5.79
PB Ratio0.65
Price to Fair Value0.65
Price to FCF-0.87
Price to Operating Cash Flow-0.87
PEG Ratio0.02
Income Statement
In the last 12 months, Kronos Bio had revenue of $9.85M and earned -$86.08M in profits. Earnings per share was -$1.43.
Revenue$9.85M
Gross Profit$8.16M
Operating Income-$80.10M
Pretax Income-$86.08M
Net Income-$86.08M
EBITDA-61.72M
Earnings Per Share (EPS)-1.43
Cash Flow
In the last 12 months, operating cash flow was -$65.43M and capital expenditures -$4.00K, giving a free cash flow of -$65.44M billion.
Operating Cash Flow-$65.43M
Free Cash Flow-$65.44M
Free Cash Flow per Share-$1.07
Dividends & Yields
Kronos Bio pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-114.67%
Earnings Yield-150.84%
Stock Price Statistics
Beta1.09
52-Week Price Change-31.58%
50-Day Moving Average0.92
200-Day Moving Average1.00
Relative Strength Index (RSI)25.07
Average Volume (3m)153.20K
Important Dates
Kronos Bio upcoming earnings date is May 7, 2025, After Close.
Last Earnings DateMar 18, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Kronos Bio as a current ratio of 7.54, with Debt / Equity ratio of 0.28
Current Ratio7.54
Quick Ratio7.54
Debt to Market Cap0.44
Net Debt to EBITDA0.97
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kronos Bio has paid $1.23M in taxes.
Income Tax$1.23M
Effective Tax Rate0.00%
Enterprise Valuation
Kronos Bio EV to EBITDA ratio is 0.04, with an EV/FCF ratio of 0.04.
EV to Sales-0.26
EV to EBITDA0.04
EV to Free Cash Flow0.04
EV to Operating Cash Flow0.04
Balance Sheet
Kronos Bio has $112.42M in cash and marketable securities with $24.90M in debt, giving a net cash position of -$87.52M billion.
Cash & Marketable Securities$112.42M
Total Debt$24.90M
Net Cash-$87.52M
Net Cash Per Share-$1.44
Tangible Book Value Per Share$1.46
Margins
Gross margin is 100.00%, with operating margin of -943.21%, and net profit margin of -874.08%.
Gross Margin100.00%
Operating Margin-943.21%
Pretax Margin-874.08%
Net Profit Margin-874.08%
EBITDA Margin-626.69%
EBIT Margin-644.11%
Analyst Forecast
The average price target for Kronos Bio is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.00
Price Target Upside28.21%
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast56.62%
EPS Growth Forecast26.48%